Hospitalization for Respiratory Syncytial Virus Infection in Young Children
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 25 (3) , 201-207
- https://doi.org/10.1097/01.inf.0000202135.24485.f8
Abstract
Because passive immunization against respiratory syncytial virus (RSV) is costly, its use should be restricted to well-defined groups of high risk children. We aimed to develop a clinical prediction rule that estimates the individual monthly risk of hospitalization for RSV infection in young children. A retrospective cohort study was conducted in the southwestern part of the Netherlands. We included children born between January 1, 1996 and December 31, 1998. Children hospitalized for proven RSV infection were compared with children not hospitalized for RSV infection. The monthly risk was estimated with a logistic regression model including 5 clinical predictors (gender, gestational age, birth weight, presence of bronchopulmonary dysplasia and age) and the mean seasonal monthly pattern of RSV infections. We compared the predictive performance of the prediction rule with the guidelines of the American Academy of Pediatrics (AAP). Information was collected on 2469 hospitalized children and 140,661 children who were 1,181,790 months at risk. All predictors were statistically significant, with age and the seasonal monthly RSV pattern having the strongest effects. The clinical prediction rule that included these predictors could better discriminate between high and low risk children than the AAP guidelines and would potentially reduce the number of immunizations by 20%. The prediction rule reliably estimates individual monthly risks of hospitalization for RSV infection in the population studied. It provides an improved index for passive immunization but further validation in other populations is required.Keywords
This publication has 28 references indexed in Scilit:
- Palivizumab Use in Very Premature Infants in the Neonatal Intensive Care UnitPublished by American Academy of Pediatrics (AAP) ,2004
- Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2003
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Optimum Dosage Regimen of Palivizumab?Therapeutic Drug Monitoring, 2002
- Hospitalisation for RSV infection in ex-preterm infants---implications for use of RSV immune globulinArchives of Disease in Childhood, 2000
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Estimating the Error Rate of a Prediction Rule: Improvement on Cross-ValidationJournal of the American Statistical Association, 1983
- Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody levelThe Journal of Pediatrics, 1981
- Bronchopulmonary dysplasia: Clinical presentationThe Journal of Pediatrics, 1979